Can-Fite BioPharma CANF
NYSE CANF
$1.85 -0.04 (-2.12%)
At close: Oct 22, 2026 · 4:00 PM EDT

Can-Fite BioPharma (CANF) Cash from Financing Activities (2012 - 2013)

Updated

Can-Fite BioPharma (CANF) reported Cash from Financing Activities of $9.64 million for FY2025, up 43.7% from $6.71 million in FY2024.

Analysis

Can-Fite BioPharma (CANF) Cash from Financing Activities (2012 - 2013) Analysis & Trends

Dating back to FY2015, Can-Fite BioPharma's Cash from Financing Activities record includes 9 years.

  • Cash from Financing Activities has a five-year compound annual growth rate of -11.4% (FY2020 to FY2025).
  • The FY2025 figure ranks as the highest annual Cash from Financing Activities since FY2021.
  • According to Business Quant data, Cash from Financing Activities came in at $6.71 million in FY2024 (-26.6%), $9.14 million in FY2023 and $20.46 million in FY2021 (+15.7%).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Eli Lilly 1,143.62 Bn 1,112.20 Bn 19.71 Bn 8.43 Bn
2 Johnson & Johnson 635.32 Bn 555.18 Bn 17.30 Bn -8.53 Bn
3 AbbVie 501.71 Bn 474.82 Bn 12.70 Bn -5.05 Bn
4 Merck 356.04 Bn 310.42 Bn 12.21 Bn 1.76 Bn
5 Novartis Ag 300.80 Bn 264.79 Bn 11.24 Bn -2.02 Bn
6 Astrazeneca 263.31 Bn 237.00 Bn 12.86 Bn -3.89 Bn
7 Amgen 238.70 Bn 194.10 Bn 7.24 Bn -1.48 Bn
8 Gilead Sciences 194.80 Bn 169.00 Bn 6.22 Bn 2.34 Bn
9 Pfizer 170.88 Bn 117.53 Bn 10.94 Bn -3.66 Bn
10 Can-Fite BioPharma 1.51 Mn -18.20 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2013 6.63 Mn
Jun 30, 2012 1.43 Mn
API Access

Can-Fite BioPharma Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=CANF&period=max&api_key=YOUR_API_KEY